Compared with Oncotype Dx and MammaPrint, uPA/PAI-1 assessment is more convenient, cost-effective and may even provide greater prognostic and predictive value for BC outcomes [15,16,17]. The gene discussed is SERPINE1; the disease is breast cancer.